Meningococcal Polysaccharide A O -Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years
Open Access
- 1 October 2013
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 20 (10), 1499-1507
- https://doi.org/10.1128/cvi.00162-13
Abstract
In this study, we compared the immunogenicities of two lots of meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A polysaccharide (PS) O -acetylation levels and evaluated their immunogenicities and safety in comparison to a licensed ACWY polysaccharide vaccine (Men-PS). In this phase III, partially blinded, controlled study, 1,170 healthy subjects aged 18 to 25 years were randomized (1:1:1) to receive one dose of MenACWY-TT lot A (ACWY-A) (68% O -acetylation), MenACWY-TT lot B (ACWY-B) (92% O -acetylation), or Men-PS (82% O -acetylation). Immunogenicity was evaluated in terms of serum bactericidal activity using rabbit complement (i.e., rabbit serum bactericidal activity [rSBA]). Solicited symptoms, unsolicited adverse events (AEs), and serious AEs (SAEs) were recorded. The immunogenicities, in terms of rSBA geometric mean titers, were comparable for both lots of MenACWY-TT. The vaccine response rates across the serogroups were 79.1 to 97.0% in the two ACWY groups and 73.7 to 94.1% in the Men-PS group. All subjects achieved rSBA titers of ≥1:8 for all serogroups. All subjects in the two ACWY groups and 99.5 to 100% in the Men-PS group achieved rSBA titers of ≥1:128. Pain was the most common solicited local symptom and was reported more frequently in the ACWY group (53.9 to 54.7%) than in the Men-PS group (36.8%). The most common solicited general symptoms were fatigue and headache, which were reported by 28.6 to 30.3% and 26.9 to 31.0% of subjects, respectively. Two subjects reported SAEs; one SAE was considered to be related to vaccination (blighted ovum; ACWY-B group). The level of serogroup A PS O -acetylation did not affect vaccine immunogenicity. MenACWY-TT (lot A) was not inferior to Men-PS in terms of vaccine response and was well tolerated.Keywords
This publication has 43 references indexed in Scilit:
- Laboratory-Based Surveillance of Neisseria meningitidis Isolates from Disease Cases in Latin American and Caribbean Countries, SIREVA II 2006–2010PLOS ONE, 2012
- The epidemiology of meningococcal disease in Latin America 1945–2010: an unpredictable and changing landscapeEpidemiology and Infection, 2012
- Maintenance of Immune Response throughout Childhood following Serogroup C Meningococcal Conjugate Vaccination in Early ChildhoodClinical and Vaccine Immunology, 2011
- Meningococcal conjugate vaccines: optimizing global impactInfection and Drug Resistance, 2011
- Meningococcal disease in Asia: an under-recognized public health burdenEpidemiology and Infection, 2011
- Epidemiological Profile of Meningococcal Disease in the United StatesClinical Infectious Diseases, 2010
- W135 Invasive Meningococcal Strains Spreading in South America: Significant Increase in Incidence Rate in ArgentinaJournal of Clinical Microbiology, 2009
- Global epidemiology of meningococcal diseaseVaccine, 2009
- Meningococcal carriage and disease—Population biology and evolutionVaccine, 2009
- Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd ImmunityThe Journal of Infectious Diseases, 2008